Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.55 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23417721 | 0.91 | TOP2A (0.55) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL13590480 | 0.82 | TOP2A (0.54) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL18133676 | 0.81 | TOP2A (0.54) | TOP2ATOP2BATMTPSAB1PLG | |
| SCHEMBL21202189 | 0.80 | TOP2A (0.52) | TOP2ATOP2BATMTPSAB1PLG | |
| SCHEMBL24703633 | 0.79 | TOP2A (0.53) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL308291 | 0.79 | ATM (0.64) | TOP2ATOP2BELANEATMALDH1A1 | |
| SCHEMBL18429543 | 0.78 | TOP2A (0.52) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL21788135 | 0.78 | TOP2A (0.51) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL21788083 | 0.78 | TOP2A (0.51) | TOP2ATOP2BELANEATMTPSAB1 | |
| SCHEMBL22394067 | 0.78 | MEN1 (0.53) | TOP2ATOP2BTPSAB1PLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-07-18 | — | — | US | disclosed |
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | TOP2A 1150/4885TOP2B 2171/4885ELANE 1609/4885 |
| US-20240238436-A1 | COMPOSITIONS INCLUDING CONJUGATED THERAPY ENHANCERS | LGMN, LPXN, LY96 | TOP2A 681/4885TOP2B 1152/4885ELANE 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.